The Two-Tier Compounding System
Compounding pharmacies in the United States operate under two distinct regulatory frameworks, established by the Drug Quality and Security Act of 2013. Understanding which tier your source operates under is the most important quality question you can ask before starting any compounded therapy.
503A pharmacies are traditional compounding pharmacies that prepare medications for individual patient prescriptions. They are regulated primarily by state boards of pharmacy — not the FDA — and are exempt from FDA manufacturing requirements including current Good Manufacturing Practice (cGMP) standards. The quality standard at a 503A pharmacy varies significantly by state, facility, and individual pharmacist practice.
503B outsourcing facilities are registered with the FDA and subject to federal oversight, including cGMP requirements, facility inspections, adverse event reporting, and product testing standards. They can produce compounded drugs in larger quantities without patient-specific prescriptions and are held to a manufacturing quality standard that closely parallels commercial pharmaceutical production.
What cGMP Actually Means in Practice
Current Good Manufacturing Practice is not a vague quality commitment — it is a specific set of FDA-enforced requirements covering facilities, personnel, equipment, production processes, quality controls, laboratory testing, and record-keeping. For sterile injectable compounds like semaglutide and peptides, cGMP compliance means:
Cleanroom production. Sterile injectables must be produced in ISO-classified cleanrooms that control particulate contamination. A 503B facility producing a sterile injectable is operating in a controlled environment with validated HVAC systems, gowning protocols, and environmental monitoring.
Lot testing. Every batch produced at a 503B facility undergoes testing before release — potency testing to confirm the drug is at labeled strength, sterility testing to confirm no microbial contamination, endotoxin testing to confirm the absence of bacterial byproducts that cause fever and inflammation, and pH and particulate testing. Facilities that cannot provide a Certificate of Analysis for each lot are not meeting this standard.
Traceability. cGMP requires complete documentation of raw material sourcing, production processes, and quality testing results. This documentation chain allows a product to be traced from the raw API supplier through every step of production to the dispensed unit. That traceability is what makes a recall possible if a problem is identified — and what distinguishes a regulated product from one that cannot account for its own inputs.
"The difference between a 503B facility and an unregistered grey-market supplier is not marginal. It is the difference between a pharmaceutical standard and no standard at all."
Why This Matters for Peptide Therapy
Peptides and GLP-1 compounds are sterile injectables. What you inject bypasses the digestive system and goes directly into your bloodstream. The stakes for contamination — endotoxins, particulates, microbial growth — are therefore categorically higher than for an oral medication. A contaminated oral supplement causes GI distress. A contaminated sterile injectable can cause severe systemic reactions.
This is precisely why the sourcing standard for injectable compounded compounds is not an area for compromise or "good enough." A 503B facility with documented lot testing, verified raw material sourcing, and a history of FDA inspection compliance is the appropriate source for any compounded injectable therapy. Everything else represents an unknown risk that no clinical benefit justifies.
Every product sourced from 503B cGMP facilities.
U.S. supply chain. Full lot traceability.
How to Verify Your Source
The FDA maintains a public list of registered 503B outsourcing facilities at fda.gov. If a compounding pharmacy claims to be a 503B facility, you can verify that registration. If they cannot point you to their registration or provide lot testing documentation for their products, that is your answer about the standard they are actually operating under.
Ask your provider: Where is this compounded? Is the facility 503B registered with the FDA? Can I see the Certificate of Analysis for this lot? A legitimate clinical provider sourcing from a legitimate facility can answer all three questions without hesitation.